Barclays PLC Has $2.79 Million Stock Position in Plexus Corp. (NASDAQ:PLXS)
Barclays PLC lifted its position in shares of Plexus Corp. (NASDAQ:PLXS) by 10.1% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 44,649 shares of the technology company’s stock after buying an additional 4,088 shares during the quarter. Barclays PLC owned about 0.15% of Plexus worth $2,791,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently bought and sold shares of PLXS. Nuveen Asset Management LLC acquired a new stake in shares of Plexus during the second quarter worth $10,217,000. Massachusetts Financial Services Co. MA lifted its holdings in shares of Plexus by 22.5% during the third quarter. Massachusetts Financial Services Co. MA now owns 708,158 shares of the technology company’s stock worth $44,267,000 after buying an additional 130,061 shares in the last quarter. Silvercrest Asset Management Group LLC lifted its holdings in shares of Plexus by 9.4% during the second quarter. Silvercrest Asset Management Group LLC now owns 1,096,872 shares of the technology company’s stock worth $64,025,000 after buying an additional 93,985 shares in the last quarter. Morgan Stanley lifted its holdings in shares of Plexus by 47.6% during the second quarter. Morgan Stanley now owns 169,681 shares of the technology company’s stock worth $9,905,000 after buying an additional 54,757 shares in the last quarter. Finally, Disciplined Growth Investors Inc. MN lifted its holdings in shares of Plexus by 1.9% during the third quarter. Disciplined Growth Investors Inc. MN now owns 2,843,609 shares of the technology company’s stock worth $177,754,000 after buying an additional 54,190 shares in the last quarter. 95.15% of the stock is owned by institutional investors.
A number of research firms have recently weighed in on PLXS. BidaskClub raised Plexus from a “buy” rating to a “strong-buy” rating in a report on Tuesday, October 15th. Zacks Investment Research raised Plexus from a “sell” rating to a “hold” rating and set a $60.00 price target for the company in a research note on Monday, September 2nd. Finally, Sidoti downgraded Plexus from a “buy” rating to a “neutral” rating in a research note on Friday, October 25th.
PLXS stock opened at $74.67 on Tuesday. The company has a market cap of $2.18 billion, a PE ratio of 21.77 and a beta of 0.98. The business has a 50-day simple moving average of $72.63 and a 200 day simple moving average of $61.47. Plexus Corp. has a 52 week low of $47.63 and a 52 week high of $77.64. The company has a quick ratio of 0.97, a current ratio of 1.78 and a debt-to-equity ratio of 0.22.
Plexus (NASDAQ:PLXS) last posted its quarterly earnings results on Wednesday, October 23rd. The technology company reported $0.93 EPS for the quarter, beating the Zacks’ consensus estimate of $0.86 by $0.07. The business had revenue of $810.00 million during the quarter, compared to the consensus estimate of $776.02 million. Plexus had a return on equity of 12.16% and a net margin of 3.43%. Plexus’s revenue for the quarter was up 1.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.96 earnings per share. On average, analysts anticipate that Plexus Corp. will post 4.09 EPS for the current fiscal year.
Plexus Corp., together with its subsidiaries, provides electronic manufacturing services in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. It offers design and development, supply chain, new product introduction, and manufacturing solutions, as well as aftermarket services. The company provides its solutions to companies in the healthcare and life sciences, industrial and commercial, communications, and aerospace and defense sectors.
See Also: What is the Hang Seng index?
Receive News & Ratings for Plexus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Plexus and related companies with MarketBeat.com's FREE daily email newsletter.